Does anyone remember the band The Fixx? I was (and still am) a big fan. For those that don’t know, The Fixx is a British new wave and rock band that originated in London in 1979. College friends Cy Curnin (vocals) and Adam Woods (drums) founded the group, first naming themselves Portraits before adding guitarist Jamie West-Oram, keyboardist Rupert Greenall, and bassist Charlie Barrett. They soon adopted the name The Fixx, securing a deal with MCA Records and releasing their debut album, Shuttered Room, in 1982.
Pharmaceutical microbiology is a rapidly evolving discipline that plays a critical role in ensuring the safety, efficacy, and quality of pharmaceutical products. The last few years have witnessed significant innovations in techniques and methods, often driven by the need for faster drug development, stricter regulatory requirements, and the emergence of new therapeutics such as biologics and personalized medicine.This paper reviews some of the newest advances in pharmaceutical microbiology as well as some of the on-going challenges to pharmaceutical microbiologists.
Oral drug delivery remains the most preferred route of administration due to its convenience, cost-effectiveness, and high patient compliance. However, conventional immediate-release (IR) formulations often result in fluctuations in plasma drug concentrations, necessitating frequent dosing and potentially causing side effects due to peak to-trough variations.
Early-stage life sciences research is a complex and resource-intensive process. Scientists weigh an overwhelming amount of information from scientific literature, including journals, Google Scholar, and PubMed. Researchers must search through vast data sources to accurately identify and contextualize all relevant biomedical information.
EMA’s Annex 1 Manufacture of Sterile Medicinal Products includes expectations for the manufacture of sterile products.1 However, the Annex essentially equates the performance of different aseptic technologies which has the effect of slowing the implementation of advanced aseptic technologies that support improvements in product/patient safety. Caution and confusion abound with respect to the use of isolation technology. There is minimal appreciation for their benefits with respect to existing practices.
This article explores drug delivery routes in the human body and highlights advanced spectroscopic methods - such as Raman, infrared, fluorescence, and nonlinear techniques - for investigating delivery mechanisms. It emphasizes their industrial relevance and presents an outlook on how these tools can accelerate drug development and precision in pharmaceutical applications.
As confidence builds in AI-powered platforms, particularly those harnessing Generative AI to distil insights and repurpose them in new formats, domain leads are eyeing up regulatory impact assessment (a critical first step in product change control) as the obvious next target for an AI-enabled overhaul. Despite the activity’s criticality, regulatory impact assessment adds little immediate value beyond continued quality assurance, compliance, and risk mitigation.
Pyrogens in general (including lipoteichoic acids, CpG DNA, viruses, and flagellin), and Gram-negative bacteria that release endotoxin, present a risk for pharmaceutical products that are administered in ways that bypass the body’s natural defenses, especially those that are infused into the bloodstream. This concern exists since endotoxin stimulates host macrophages to release inflammatory cytokines, and it can cause endotoxic shock.
In the pharmaceutical industry, ensuring the quality and safety of products is paramount. As part of this commitment, regulatory bodies and industry standards have established guidelines for monitoring microbial contamination in cleanrooms and controlled environments.
More than five years have passed since COVID-19 was declared a global pandemic, marking the beginning of a healthcare crisis that has claimed millions of lives and continues to shape our world today. Early efforts to contain the elusive and ever-evolving SARS-CoV-2 virus demanded unprecedented collaboration among nations, healthcare systems, and industry innovators. The pandemic stands as a defining moment in history - not only for its profound toll on human life, but also for how it fundamentally reshaped the landscape of modern drug discovery.
If there’s one thing we’ve learned over the last few years, pharmaceutical manufacturers are being asked to do more with less time, fewer resources, and tighter space. The push to expand production and respond to market needs quickly, while still meeting strict compliance standards, has made life on the plant floor much more complicated.
Don Singer, Senior Global Microbiology Consultant, New Beginnings Microbiology: It has been almost two decades since quality systems have been designed, implemented, and been on a continuous improvement path, while technology and validation in microbiology have taken a slightly different and more constrained path.
End-to-end (E2E) continuous biomanufacturing refers to the integrated, uninterrupted process for producing biologics, such as monoclonal antibodies, vaccines, and enzymes, directly from raw materials to the final product. This system contrasts with traditional batch processes that have discrete stages, starting and stopping for each batch.
Pyrogens are contaminant substances in injectable drugs or implants that can provoke harmful reactions in patients, ranging from mild fever to severe, potentially life-endangering symptoms. Among the various pyrogens, endotoxins—lipopolysaccharides of gram-negative bacteria—are the most commonly found in pharmaceutical products. All other pyrogens are classed as non-endotoxin pyrogens (NEPs).
The purpose of this column is to highlight
and summarize recent key patents in the pharmaceutical arena issued by the US
Patent Office in April and May, 2025.